Trial Information

Clinical Follow-up of Patients Treated With Radiofrequency Ablation of Lung Masses.

Radiofrequency ablation (RFA) is a relatively new treatment for localized forms of cancer.
It requires that a device called a needle-electrode be placed in the tumor. Radiofrequency
energy can be passed through this needle-electrode that heats the tissue surrounding the
needle tip. If the heating effect is intense enough and maintained for a long enough period
of time, the cells in the treated area will be destroyed. RFA has been used in the lung to
treat metastases from cancers originating in other sites, and cancers other than small cell
carcinoma (Non-small cell lung cancer, NSCLC) that arise in the lung itself.

Pre-treatment assessment includes evaluation of the patient and the tumor itself; this
determines whether the patient meets the entry criteria. These criteria are:

- Patient has a biopsy-proven NSCLC, with no other sites of disease, and with a tumor
small enough to treat (usually <4 cm). Clinical stage I NSCLC.

- Patient is not a candidate for surgical removal of the cancer, or refused surgery.

- Patient is not a candidate for radiation therapy, or refused radiation therapy.

- Patient has > 6 month life expectancy. The procedure is performed similar to a needle
biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to
needle placement for CT-guided biopsy. Appropriate positioning of the needle-electrode
is confirmed by CT imaging. Radiofrequency energy is applied to the needle-electrode
and the tissue is monitored continuously for electrical changes that indicate tissue
destruction. After completion of the treatment, the needle-electrode is removed. The
patient is followed for at least three hours prior to discharge. Complications that can
be discovered at this time are pulmonary hemorrhage (bleeding in the lung) and
pneumothorax (leakage of air from the lung at the site of needle puncture). Subsequent
follow-up usually consists of a CT scan at three months and six months after the RFA,
and then at six month intervals after that, to see whether the tumor successfully has
been transformed into a scar, or continues to grow.

This follow-up is conducted by the referring physician, who may not be associated with this
institution. We gather and record this follow-up information until the patient dies, has
documented recurrence of the cancer, or completes five years of post- treatment observation.
In the cases of recurrence, we also determine whether the tumor is re-growing at the
treatment site, or at distant sites that appeared to be uninvolved at the time of treatment.

Statistical analysis will be performed using de-identified patient data. Measures of
interest include lifetable determination of median survival and 5-year overall survival.
Patients will undergo no study-related procedures during the follow-up period. Chemotherapy
given at any time following RFA, at the discretion of a medical oncologist, will not result
in exclusion of the patient from analysis.